I agree that this site is using cookies. You can find further informations here.
X
Maojin You
28  results:
Search for persons X
?
1

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 a..:

Huang, Yufan ; You, Maojin ; Wu, Qundan.
Frontiers in Pharmacology.  14 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
2

Cost-effectiveness analysis of dostarlimab plus carboplatin..:

You, Maojin ; Zeng, Xiaoling ; Zhang, Jinrong...
Frontiers in Immunology.  14 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
3

Cost-effectiveness analysis of transarterial chemoembolizat..:

He, Ying ; Lin, Wangchun ; Cai, Zhongjie...
Frontiers in Pharmacology.  14 (2023)  - p. , 2023
Link: https://doi.org/10.3389/..
 
?
4

Cost-effectiveness analysis of sintilimab plus chemotherapy..:

You, Maojin ; Huang, Yufan ; Cai, Zhongjie...
Frontiers in Oncology.  12 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
5

Cost-effectiveness analysis of adebrelimab combined with ch..:

You, Maojin ; Chen, Ruijia ; Wu, Qingfeng...
Frontiers in Pharmacology.  13 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
6

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplati..:

Chen, Ruijia ; Zhang, Yalan ; Lin, Kongying...
Frontiers in Pharmacology.  13 (2022)  - p. , 2022
Link: https://doi.org/10.3389/..
 
?
7

Table1_Cost-effectiveness analysis of transarterial chemoem..:

Ying He ; Wangchun Lin ; Zhongjie Cai...
doi:10.3389/fphar.2023.1219694.s001.  , 2023
Link: https://doi.org/10.3389/..
 
?
8

Table1_Cost-effectiveness analysis of zolbetuximab plus mFO..:

Yufan Huang ; Maojin You ; Qundan Wu.
doi:10.3389/fphar.2023.1238009.s001.  , 2023
Link: https://doi.org/10.3389/..
 
?
9

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 a..:

Yufan Huang ; Maojin You ; Qundan Wu.
https://www.frontiersin.org/articles/10.3389/fphar.2023.1238009/full.  , 2023
Link: https://doi.org/10.3389/..
 
?
10

Cost-effectiveness analysis of transarterial chemoembolizat..:

Ying He ; Wangchun Lin ; Zhongjie Cai...
https://www.frontiersin.org/articles/10.3389/fphar.2023.1219694/full.  , 2023
Link: https://doi.org/10.3389/..
 
?
11

Cost-effectiveness analysis of dostarlimab plus carboplatin..:

Maojin You ; Xiaoling Zeng ; Jinrong Zhang...
https://www.frontiersin.org/articles/10.3389/fimmu.2023.1267322/full.  , 2023
Link: https://doi.org/10.3389/..
 
?
12

DataSheet_1_Cost-effectiveness analysis of dostarlimab plus..:

Maojin You ; Xiaoling Zeng ; Jinrong Zhang...
doi:10.3389/fimmu.2023.1267322.s001.  , 2023
Link: https://doi.org/10.3389/..
 
?
13

Cost-effectiveness analysis of adebrelimab combined with ch..:

Maojin You ; Ruijia Chen ; Qingfeng Wu...
https://www.frontiersin.org/articles/10.3389/fphar.2022.1019826/full.  , 2022
Link: https://doi.org/10.3389/..
 
?
14

Image_1_Cost-effectiveness analysis of sintilimab plus chem..:

Maojin You ; Yufan Huang ; Zhongjie Cai...
doi:10.3389/fonc.2022.986762.s001.  , 2022
Link: https://doi.org/10.3389/..
 
?
15

Cost-effectiveness analysis of sintilimab plus chemotherapy..:

Maojin You ; Yufan Huang ; Zhongjie Cai...
https://www.frontiersin.org/articles/10.3389/fonc.2022.986762/full.  , 2022
Link: https://doi.org/10.3389/..
 
1-15